You must have the free Adobe Reader to view these forms. Get Adobe Reader.
New Patients - These forms will be requested prior to your first visit.
Welcome and thank you for choosing the Institute for Human Reproduction for your treatment. Below is our office policies and procedures to ensure that you receive the best care and treatment as possible. If you have any questions regarding these policies, please feel free to ask any of the staff for assistance. If you have any suggestions that may assist you or future patients with their treatment in our office, please bring them to the attention of the office manager. Good luck with your treatment.
Our office is open from 8:00 AM to 5:00 PM on Monday thru Friday. Patients are seen on the weekend only during treatments. No routine visits will be scheduled on the weekend.
Our telephone is answered by our staff with an automated system backup to give you, the patient, the fastest access to our staff. There are options for appointment scheduling, billing/insurance and the nurses. All staff has voice mail availability if they are unable to answer their phone. The nurses will answer the phone unless they are assisting the physician or on the phone with another patient. The nurse's voicemail is available 24 hours should you want to call and leave your message after hours. The voice mail will be accessed the next business day. Our IVF nurse is on call every evening and weekend until 10:00PM for urgent calls. There is a physician on call 24 hours for medical emergencies.
Missed and cancelled appointments
If you are unable to make a scheduled appointment, please cancel with our office with at least 24 hours notice. This gives our office the opportunity to offer that appointment time to another patient.
IHR is contracted with most major insurance companies. Our office will file for all covered procedures on any plan that IHR is contracted with. If IHR is not contracted with your insurance company, you may have what is called “out of network benefits” that will cover a lower portion of our fees. Be sure and discuss your insurance plan with our billing/insurance office regarding your out-of-pocket expenses. Unless we have written verification of Infertility coverage, you will be required to pay all Infertility procedures/treatments at the time of service. For written verification you may send a predetermination letter to your insurance company or bring in a copy of your individual plan. If insurance has not paid a claim in 90 days, it will become the responsibility of the insured. You are the insured and a consumer and have the right and authority to contact your insurance company and appeal denials. Sometimes a complaint from the actual insured will move the payment process along more expediently. You may contact our billing/insurance office for any assistance or questions you may have in appealing an insurance claim. If you have a question about fees, please call our billing/insurance office for assistance.
The Institute for Human Reproduction (IHR) wants to make achieving your dreams of parenthood the most manageable and convenient possible. We have partnered with two global financing leader to administer loan transactions for IHR’s Infertility Program participants.
Fertility financing options include: easy no-cost, online application process, no initial payment, no prepayment penalty and secured loans with preferred discount rates. All fertility and IVF financing is at the sole discretion of and subject to the lending institution's credit approval. Click here, to learn more about Lending Club Infertility Financing.
Here are some of the benefits you’ll receive with a loan from Prosper Healthcare Lending:
• Immediate decisions for loans under $35,000
• Longer terms for lower monthly payments
• No collateral required
• No prepayment penalties
• Fast & easy loan inquiry process
• 100% Confidential
Diseases & Conditions
Endometriosis occurs when tissue like that lines the inside of the uterus grows outside the uterus. The two most common symptoms, pain and infertility, can deeply affect a woman's quality of life. In many cases, women who receive treatment for their endometriosis pain are able to get pregnant. But this is not the case for all women. Researchers estimate that nearly 5.5 million women in North America have endometriosis. Endometriosis is not a cancerous condition. Also, current research does not prove an association between endometriosis and uterine, cervical, endometrial, or ovarian cancers. For more information on endometriosis.
Polycystic Ovary Syndrome (PCOS)
PCOS is one of the most common causes of female infertility. PCOS is a condition in which a woman’s ovaries and, in some cases the adrenal glands, produce more androgens (a type of hormone) than normal. High levels of these hormones interfere with the development and release of eggs as part of ovulation. As a result, fluid-filled sacs or cysts can develop on the ovaries. Researchers estimate that 5 percent to 10 percent of women in the United States have PCOS. Research shows that women with PCOS are also at higher risk than women without the disorder to experience other health problems, such as insulin resistance, obesity, high blood pressure, and heart disease. Although researchers are still trying to learn about this disease, and to find ways to treat the infertility associated with PCOS, there have been some promising leads. One group of researchers may have found a possible treatment for the infertility related to PCOS. For more information about PCOS.
Premature Ovarian Failure (POF)/Primary Ovarian Insufficiency (POI)
Health care providers use the terms POF or POI to describe a stop in normal functioning of the ovaries in a woman under the age of 40. (Women's ovary function naturally begins to decline at age 40). In POF, the ovaries stop making eggs and stop making certain hormones. An estimated 250,000 women under age 40 have POF in the United States. Health care providers used to call this condition premature menopause, but premature ovarian failure is actually much different than menopause. For more information on POF/POI.
Uterine fibroids are the most common, non-cancerous tumors in women of childbearing age. These tumors are made of muscle cells and other tissues that grow within the wall of the uterus. Uterine fibroids are the cause of more than 200,000 hysterectomies each year. Uterine fibroids are not cancerous, nor are they associated with cancer. In very rare instances, less than 0.1 percent of cases, fibroids do develop into cancer. For more information about uterine fibroids.
IHR provides free videos, articles and audio on infertility and how infertility can be treated. Topics include ovary transplant surgery, vasectomy reversal, in vitro fertilization (IVF), fertility preservation options and much more. IHR offers many different treatments for both male and female infertility.
Below are Video clips and audio excerpts on infertility science and treatment
IHR experts are continuing to advance the field of infertility
Below are listing of IHR infertility publications
|1.||Biotechnology of Human Reproduction. Revelli, A, Tur-Kaspa I, Holte JG, Massobrio M, Editors. New York, The Parthenon Publishing Group, 2003.|
|2.||Ultrasound Imaging in Reproductive Medicine: Advances in Infertility Work-up, Treatment, and ART. Stadtmauer L, Tur-Kaspa I, Editors. New York, Springer Publisher, 2014.|
|Refereed Articles in Scientific Journals|
|1.||Brautbar C, Freier S, Ashkenazi A, Dekelbaum R, Tur-Kaspa I, Amar A, Cohen I, Sharon R, Abecasis C, Levene C, Cohen T, Albert E. Histocompatibility determinants in patients with coeliac disease: population and family study. Tissue Antigens 1981;17:313-22.|
|2.||Granat M, Tur Kaspa I, Zylber-Katz E, Shenker JG. Reduction of peritoneal adhesion formation by colchicine: A comparative study in the rat. Fertil Steril 1983;40:369-72.|
|3.||Flugelman MY, Hasin Y, Tur Kaspa I, Friedlander Y, Gotsman MS. Prediction of in-hospital ventricular fibrillation from admission data in acute myocardial infarction. Clin Cardiol 1983;6:156-62.|
|4.||Galun E, Burstein R, Assia E, Tur Kaspa I, Rosenblum J, Epstein Y. Changes of white blood cell count during prolonged exercise. Int J Sports Med 1987;8:253-5.|
|5.||Galun E, Burstein R, Tur Kaspa I, Assia E, Epstein Y. Prediction of physical performance through muscle enzymes activity. Eur J Appl Physiol, 1988;57:597-600.|
|6.||Lurie M, Tur Kaspa I, Weill S, Katz I, Goldenberg S. Ciliary ultrastructure of respiratory and fallopian tubal epithelium in a sterile woman with kartagener's syndrome: A quantitative estimation. Chest, 1989;578-81.|
|7.||Oelsner G, Menashe Y, Tur Kaspa I, Ben-Rafael Z, Blankstein Y, Mashiach S, Serr DM. The role of gonadotropins in the etiology of ectopic pregnancy. Fertil steril 1989;52:514-6.|
|8.||Tur Kaspa I, Confino E, Friberg J, Myers SA, Dudkiewicz AB, Gleicher N. Ovarian stimulation protocol for in vitro fertilization with gonadotropins releasing hormone agonist widened the implantation window. Fertil Steril 1990;53:859-64 (Fertil Digest 1991;2:15-16).|
|9.||Confino E, Tur Kaspa I, DeCherney A, Corfman R, Coulam C, Robinson E, Haas G, Katz E, Vermesh M, Gleicher N. Transcervical balloon tuboplasty: A multicenter study. JAMA 1990;2079-82 (Year Book of Infertility 1991;391-3).|
|10.||Tur Kaspa I, Dudkiewicz AB, Confino E, Gleicher N. Pooled sequential ejaculates: A way to increase total number of motile spermatozoa from oligozoospermic males. Fertil Steril 1990;54:906-9. (Year Book of Infertility 1991;145-7).|
|11.||Tur Kaspa I, Dudkiewicz AB. Is oligospermia a seasonal phenomena? N Eng J Med (let) 1990;323:1564.|
|12.||Tur Kaspa I. Hyperbaric oxygen therapy for air embolism complicating operative hysteroscopy .Am J Obstet Gynecol (let) 1990;163:680-1.|
|13.||Tur Kaspa I, Gleicher N. Diagnosis: Eclampsia. Hosp Med 1990; 26:55-68.|
|14.||Galun E, Tur Kaspa I, Assia E, Burstein R, Strauss N, Epstein Y, Popovtzer MM. Hyponatremia induced by exercise: a 24-hour endurance march study. Miner Electrolyte Metab 1991;17:315-20.|
|15.||Confino E, Tur Kaspa I, Gleicher N. Sonographic transcervical balloon tuboplasty. Hum Reprod 1992;7:1271-3.|
|16.||Hales DB, Xiong Y, Tur-Kaspa I. The role of cytokines in the regulation of leydig cell p450c17 gene expression. J Steroid Biochem Molec Biol 1992;43:907-14.|
|17.||Gleicher N, Confino E, Corfman R, Coulam C, DeCherney A, Haas G, Katz E, Robinson E, Tur Kaspa I, Vermesh M. The multicenter transcervical balloon tuboplasty study: conclusions and comparison to alternative technologies. Hum Reprod 1993;8:1264-71.|
|18.||Tur Kaspa I, Gleicher N. Transcervical balloon tuboplasty. The Female Patient 1993;18:65- 69.|
|19.||Tur Kaspa I. Transcervical tubal catheterization for the diagnosis and treatment of proximal tubal occlusion. Ob/Gyn Update (Hebrew) 1993;8:4-6.|
|20.||Oelsner G, Goldenberg M, Admon D, Pansky M, Tur Kaspa I, Rabinovitch O, Carp HJ, Mashiach S. Salpingectomy by operative laparoscopy and subsequent reproductive performance. Hum Reprod 1994:9:83-6.|
|21.||Ralt D, Manor M, Cohen-Dayag A, Tur Kaspa I, Ben-Shlomo I, Makler A, Yuli I, Dor J, Blumberg S, Mashiach S, Eisenbach M. Chemotaxis and chemokinesis of human spermatozoa to follicular factors. Biol Reprod 1994;50:774-85.|
|22.||Cohen-Dayag A, Ralt D, Tur Kaspa I, Manor M, Makler A, Dor J, Mashiach S, Eisenbach M. Sequential acquisition of chemotactic responsiveness by human spermatozoa. Biol Reprod 1994;50:786-90.|
|23.||Tur Kaspa I, Maor Y, Levran D, Yonish M, Mashiach S, Dor J. How often should infertile men have intercourse to achieve conception? Fertil Steril 1994;62:370-5 (Year Book of Infertility 1995).|
|24.||Tur Kaspa I, Maor Y, Dor J, Mashiach S. Frequency of intercourse for couples trying to conceive. Lancet (Commentary) 1994:344:766.|
|25.||Eisenbach M, Tur Kaspa I. Human sperm chemotaxis is not enigmatic anymore. Fertil Steril (Editorial) 1994;62:233-5.|
|26.||Lev EI, Hendler I, Siebner R, Tashma Z, Wiener Tur Kaspa I. Creatine kinase activity decrease with short-term freezing. Enzyme & Protein 1994-95;48:238-42.|
|27.||Cohen-Dayag A, Tur Kaspa I, Dor J, Mashiach S, Eisenbach M. Sperm capacitation in humans is transient and correlates with chemotactic responsiveness to follicular factors. Proc Natl Acad Sci USA 1995;92:11039-43.|
|28.||Tur Kaspa I, Maor Y, Dor J. Male infertility. N Eng J Med (let) 1995;332:1790.|
|29.||Amital H, Tur Kaspa I, Tashma Z, Hendler I, Shoenfeld Y. Catalytic antibodies. Structure and possible applications. Methods Mol Biol 1995;51:203-10.|
|30.||Tur-Kaspa I, Maor Y, Weissenberg R, Madgar I, Aderka D, Dor J, Mashiach S, Wallach D. High levels of soluble p55-TNF receptors in seminal and prostatic fluids of normal and infertile men. J Urol 1996;155:1436-8.|
|31.||Bider D, Amoday I, Tur Kaspa I, Livshits A, Dor J. The addition of a glucocorticoid to the protocol of programmed oocytes retrieval for in-vitro fertilization - a randomized study. Hum Reprod 1996;11:1606-8.|
|32.||Friedman A, Kaufer-Nachum D, Shemer J, Hendler I, Soreq H, Tur Kaspa I. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nature Med 1996, 2:1382-5.|
|33.||Golan A, Tur Kaspa I. The management of the infertile patient with proximal tubal occlusion. Hum Reprod (Editorial) 1996;11:1833-4.|
|34.||Soriano D, Dulitzki M, Tur Kaspa I, Barkai G, Mashiach S, Seidman DS. Postpartum angina- like symptom complex associated with Syntometrine. Prenatal and Neonatal Med 1997; 60-2.|
|35.||Bider D, Blankstein J, Levron J, Tur Kaspa I. Gonadotropins and glucocorticoid therapy for “low responders” - a controlled study. J Assist Reprod Genet 1997;14:328-31.|
|36.||3Aizenstein O, Lehavi O, Tur Kaspa I. Ciprofloxacin treatment for pregnant or lactating women, and children? Harefuah 1997; 132: 283-8.|
|37.||Tur Kaspa I, Seideman DS, Soriano D, Greenberg I, Dor J, Bider D. Hysterosalpingography with a balloon catheter versus a metal cannula: a prospective, randomized, blinded, comparative study. Hum Reprod 1998;13:75-7.|
|38.||Bider D, Shine S, Tur Kaspa I, Levron J, Dor J. Cortisol concentrations in follicular fluid of “low-responder” patients. Hum Reprod 1998;13:27-9.|
|39.||Jaiswal BJ, Cohen-Dayag A, Tur Kaspa I, Eisenbach I. Sperm capacitation is, after all, a prerequisite for both partial and complete acrosome reaction. FEBS Lett. 1998;427:309-13.|
|40.||Bider D, Blankstein J, Tur Kaspa I. Fertility in anovulatory patients after primary cesarean section. J Reprod Med 1998;43:869-71.|
|41.||Tur Kaspa I, Yuval Y, Bider D, Levron J, Dor J. Difficult or repeated embryo transfers do not adversely affect pregnancy rates in IVF. Hum Reprod 1998;13:2452-2455.|
|42.||Jaiswal BS, Eisenbach M, Tur-Kaspa I. Detection of partial and complete acrosome reaction in human sperm: which inducers and probes to use? Mol Hum Reprod 1999;5:214-9.|
|43.||Jaiswal BS, Tur-Kaspa I, Dor J, Mashiach S, Eisenbach M. Human sperm chemotaxis: Is progesterone a chemoattractant? Biol Reprod 1999;60:1314-9.|
|44.||Tur-Kaspa I, Lev EI, Hendler I, Siebner R, Shapira Y, Shemer J. Preparing hospitals for toxicological mass casualties events. Crit Care Med, 1999;27:1004-8.|
|45.||Eisenbach M, Tur-Kaspa I. Do human eggs attract spermatozoa? BioEssays 1999;21:203- 210.|
|46.||Lev EI, Tur-Kaspa I, Ashkenazy I, Reiner A, Faraggi D, Shemer J, Argov Z. Distribution of serum creatine kinase activity in young healthy persons. Clin Chim Acta 1999; 279:107-5.|
|47.||Bider D, Hourvitz A, Tur Kaspa I, Direnfeld M, Dor J. Dexamethasone supplementation to gonadotropin stimulation for in vitro fertilization in polycystic ovarian disease. J Assisted Reprod Genet 1999;16:233-5.|
|48.||Bider D, Livshitz, Tur Kaspa I, Shulman A, Levron J, Dor J. Incidence and perinatal outcome of multiple pregnancies after intracytoplasmic sperm injection compared to standard in vitro fertilization. J Assisted Reprod Genet 1999:16:221-6.|
|49.||Tur Kaspa I, Segal S, Moffa F, Massobrio M, Meltzer S. Viagra for temporary erectile dysfunction during treatments with assisted reproductive technologies. Hum Reprod 1999;14:1783-84.|
|50.||Gemer O, Shenhav S, Segal S, Tur-Kaspa I. Thyroid hormone levels in cord blood of infants with acidemia at birth. Eur J Obstet Gynecol Reprod Biol 2000;93:53-5.|
|51.||Shapira M, Tur-Kaspa I, Bosgraaf L, Livni N, Grant AD, Grisaru D, Korner M, Ebstein RP, Soreq H. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum Mol Genet 2000;9:1273-81.|
|52.||Katz N and Tur-Kaspa I. Cytoplasmic maturity of metaphase II human oocytes: Biologic importance and clinical implication for In Vitro Fertilization. Reprod Technol 2000;10:170-73.|
|53.||Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N Engl J Med 2000;343:2-7.|
|54.||Carp H, Dolitzky M, Tur-Kaspa I, Inbal A. Hereditary thrombophilias are not associated with a decreased live birth rate in women with recurrent miscarriage. Fertil Steril 2002;78:58-62.|
|55.||Revelli A, Ghigo D, Moffa F, Massobrio M, Tur-Kaspa I. Guanylate cyclase activity and sperm function. Endocrine Reviews 2002;23:484-94.|
|56.||Sun F, Giojalas LC, Rovasio RA, Tur-Kaspa I, Sanchez R, Eisenbach M. Lack of Species- specificity in Mammalian Sperm Chemotaxis. Develop Biol 2003;255:423-27.|
|57.||Bahat A, Tur-Kaspa I, Gakamsky A, Giojalas LC, Eisenbach M. Thermotaxis of mammalian sperm cells – a potential navigation mechanism in the female genital tract. Nature Med 2003;9:149-50.|
|58.||Gemer O, Kapustian V, Kroll D, Tur-Kaspa I, Segal S. Can perioperative factors predict successful hysteroscopic endometrial ablation? J Reprod Med 2003;48:.|
|59.||Rechitsky S, Kuliev A, Tur-Kaspa I, Morris R, Verlinsky Y. Preimplantation genetic diagnosis with HLA matching. Reproductive BioMedicine Online 2004, 9: 210–221.|
|60.||Sun F, Bahat A, Gakamsky A, Girsh E, Katz N, Giojalas LC, Tur-Kaspa I, Eisenbach M. Human sperm chemotaxis: both the oocyte and its surrounding cumulus cells secrete sperm chemoattractants. Sun et al. Hum. Reprod..2005; 20: 761-767.|
|61.||Bahat A, Eisenbach M, Tur-Kaspa I. Periovulatory increase in temperature difference within the rabbit oviduct. Hum Reprod, 2005;20:2118-21.|
|62.||Verlinsky y, Tur-Kaspa I, Cieslak J, Bernal B, Morris R, Taranissi M, Kaplan B, Kuliev A. Preimplantation testing for chromosomal disorders improves reproductive outcome of poor prognosis patients. Reproductive BioMedicine Online 2005; 11: 219–25.|
|63.||Kuliev A, Rechitsky R, Verlinsky O, Tur Kaspa I, Kalakoutis G, Angastiniotis M, Verlinsky Y. Preimplantation diagnosis and HLA typing for haemoglobin disorders. Reproductive BioMedicine Online 2005;11:362-70.|
|64.||Kuliev A, Rechitsky R, Tur Kaspa I, Verlinsky Y. Preimplantation genetics improving access to stem cell therapy. Ann N.Y. Acad Sci 2005; 1054:1-5.|
|65.||Rechitsky S, Kuliev A, Sharapova T, Laziuk K, Ozen S, Barsky I, Verlinsky O, Tur-Kaspa I, Verlinsky Y. Preimplantation HLA typing with aneuploidy testing. Reproductive BioMedicine Online 2006;12: 89–100.|
|66.||Kuliev A, Rechitsky S, Laziuk K, Verlinsky O, Tur-Kaspa I, Verlinsky Y. Pre-embryonic diagnosis for Sandhoff disease. Reproductive BioMedicine Online 2006;12:328–333.|
|67.||Rabinson J, Orvieto R, Shapira A, Brownstein Z, Meltzer S, Tur-Kaspa I. Mullerian anomalies, hearing loss and Connexin 26 mutations. Fertil Steril 2006:85:1824-25.|
|68.||Cieslak-Janzen J, Tur-Kaspa I, Ilkevitch Y, Bernal A, Morris R, Verlinsky Y. Multiple micromanipulations for PGD does not affect embryo development to blastocyst. Fertil Steril 2006, 85:1826-29.|
|69.||Tur-Kaspa I, Gal M, Hartman M, Hartman J, Hartman A. A Prospective Evaluation of Uterine Abnormalities by Saline Infusion Sonohysterography (SIS) in 1009 Women with Infertility or Abnormal Uterine Bleeding. Fertil Steril 2006; 86:1731–35.|
|70.||Verlinsky Y Rechitsky S, Sharapova T, Laziuk K, Barsky I, Verlinsky O, Tur-Kaspa I, Kuliev A. Preimplantation diagnosis for immunodeficiencies. Reproductive BioMedicine Online 2007;14:214-223.|
|71.||Zohav E, Orvieto R, Anteby EY, Segal O, Meltzer S, Tur-Kaspa I. Low endometrial volume may predict early pregnancy loss in women undergoing in vitro fertilization. J Assist Reprod Genet 2007; 24:259-61.|
|72.||Munn S, Gianaroli L, Tur-Kaspa I, Magli C, Sandalinas M, Grifo J, Cram D Kahraman S, Verlinsky Y, Simpson JL. Substandard application of preimplantation genetic screening may interfere with its clinical success. Fertil Steril 2007;88:781-84.|
|73.||Revelli A, Dolfin E, Gennarelli G, Lantieri T, Massobrio M, Holte JG, Tur-Kaspa I. Low-dose acetylsalicylic acid plus prednisolone as an adjuvant treatment in IVF: a prospective, randomized study. Fertil Steril 2008;90:1685-91.|
|74.||Coulam CB, Roussev RG, Lerner S, Zlatopolsky Z, Ilkevitch Y, Tur-Kaspa I. How to predict implantation? No correlation between embryonic aneuploidy and soluble HLA-G concentrations. Fertil Steril 2009;91:2408–13.|
|75.||Tur-Kaspa I, Ezcurra D. GnRH antagonist, cetrorelix, for pituitary down-regulation in modern, patient-friendly assisted reproductive technology. Expert Opin. Drug Metab. Toxicol. 2009:5(10):1323-36 (Invited Review).|
|76.||Tur-Kaspa I, Aljadeff G, Rechitsky S, Grotjan HE, Verlinsky Y. PGD for all cystic fibrosis carrier couples: novel strategy for preventive medicine and cost analysis. Reproductive BioMedicine Online 2010;21:186-95.|
|77.||Hershberger PE, Schoenfeld C, Tur-Kaspa I. Unraveling Preimplantation Genetic Diagnosis for Couples at High-Genetic-Risk: Applications, Procedures, and Implications for Nurses at the Front Line of Care. Nurs Womens Health 2011;15(1): 36–45.|
|78.||Tur-Kaspa I. Fear no pain: uterine cavity and tubal patency assessment tests should be pain free. Ultrasound Obstet Gynecol, 2012; 39:247-251. (Invited Opinion).|
|79.||Hershberger PE, Gallo AM, Kavanaugh K, Olshansky E, Schwartz A, Tur-Kaspa I. The decision-making process of genetically at-risk couples considering preimplantation genetic diagnosis: Initial findings from a grounded theory study. Soc Sci Med. 2012 74(10):1536-43|
|80.||Tur-Kaspa I. Clinical Management of in vitro fertilization (IVF) with Preimplantation genetic diagnosis (PGD). Semin Reprod Med 2012; 30:313-326 (Invited Review).|
|81.||Uflacker A, Doraiswamy PM, Rechitsky S, See T, Geschwind M, Tur-Kaspa I. Preimplantation Genetic Diagnosis (PGD) for Genetic Prion Disorder Due to F198S Mutation in the PRNP Gene. JAMA Neurol. 2014;71:484-86.|
|82.||Tur-Kaspa I, Jeelani R, Doraiswamy PM. Preimplantation genetic diagnosis (PGD) for inherited neurological disorders. Nature Reviews Neurology 2014;10: 417-24.|
|83.||Tur-Kaspa I, Jeelani R. Clinical guidelines for IVF with PGD for HLA matching. Reproductive BioMedicine Online 2014, in press. (DOI: http://dx.doi.org/10.1016/j.rbmo.2014.10.007)|
Here is a sample of the patient commentary we receive at the Institute for Human Reproduction. If you would like to send us a brief summary of your experience, please send us an e-mail. Include a photo, too, if you'd like!
We wanted to send you a note to share our joyful news - Kate was born on June 14th weighing 8lbs., 7oz. and measuring 20.5"! She is a beautiful, healthy baby and everyone here is doing great! We would not have our precious baby with us today if it was not for you - thank you from the bottom of our hearts!!! We will be seeing you again in 2 years for a repeat performance!
I read and compared many centers over the internet and every person who had been successful went to RGI-IHR. That’s why we chose your facility. It was a great and I continue to refer people to you in support groups of people who are in the same situation as we are.
Thank you!!! We will continue to refer you to others.
Outstanding experience. The nursing and physician staff were outstanding. Highly
recommend. They are one stop shopping from the IVF to the post pregnacy genetic
testing to outstanding genetic consulting. Everything is offered in one location.
Their experience and knowledge is vast. They made my experience as an busy surgeon
great. I was also out of state and they worked with me in all aspects of my schedule
and travel. They were very easy to contact via phone during and after business
hours. Their caring additude and wealth of knowledge was great. They were the
third program I had used and we were successful in producing a baby boy. They
offered the state of the art technology which resulted in our success. Their
amount of volume and experience was so valuable. They are one of the US/world
leading centers in PGD which is what initially attracted me to their center.
Each step of the way was just as good has their world wide PGD reputation: from
my telephone interview with Dr. Tur Kaspa to my daily telephone dealings with
his outstanding nursing/MD staff to the painless egg retrieval/transfer and the
final CVS .
Thank you very much for your professional and first class care. Love,the Proud Parents of a healthy baby
Our little boy has finally arrived. We are very proud, happy and sleep deprived, We can't thank all of you enough. IVF parents, Indiana
Thank you for helping us realize our dream.
Parents of a healthy baby girl, Michigan
Thank you all for everything you have done for us. You have given us two perfectly healthy baby boys. Words can't express our thanks.
You have been so kind, so professional, so wonderful that words could never explain my gratitude. I appreciate all your calls and answering my questions, etc. Thank you so very much.
We want to thank you for all you did for us. Your support and encouragement helped us through this trying time in our life. With your help we were able to give birth to two healthy little boys! We hope to one day be able to say thank you in person.
We are overjoyed with our miracle baby - born healthy with the help of PGD and IVF. She is just perfect and we couldn't be happier! Wishing you all the best and lots of thanks, IVF patients, Chicago, IL
Thank you again for all your help. Your clinic has truly been a miracle for us! Parents of a healthy baby born from PGD, Wichita, KS
We want to thank you so much for all your help and support while we were in Chicago. You really helped us a lot and we appreciate it so much. We are doing fine and will let you know when the good news arrives!! Stay well and all the best! Thank you again! A Pregnant patient
We wanted you to know how much we appreciated everything you did for us through the entire IVF process. With your help, we now have a beautiful son. He is such a blessing and a gift to our family. Thank you for being such a professional and for being such a wonderful genetic counselor. Parents of a healthy baby born, Indianapolis, IN
I just wanted to write you and thank you for all of your help during our IVF cycle. It was successful and I became pregnant with twins and had two beautiful baby girls! They are both healthy and we couldn't be happier. You were so very helpful in our meeting with you and on the phone numerous times. You always took the time to answer my questions and you always seemed very happy to help. You honestly made one of the most stressful experiences of my life a lot easier to get through. I thank you so much for your help. You have honestly helped make our dream come true! Thank you A former aneuploidy patient and proud mother of twin girls, Chicago, IL
On this page find out what’s new in Infertility and what’s happening at IHR. We post updates on happenings, events, press clippings, video coverage and IHR-related activities that may be of interest to patients, the media, and professional colleagues.
|Oct. 22, 2014||Free IVF Cycle Lottery: In celebration of Dr. Cohen joining IHR
In celebration of Dr. Cohen joining IHR and opening a third location at Bedford Park, Illinois, IHR is offering a Free In-Vitro Fertilization (IVF) treatment to a couple in need but unable to afford infertility treatment.
|August 15, 2010||Awarded ASRM Star Award
The Star Award is given to ASRM members, nominated by their peers, who have continuously contributed 10 or more years in reproductive field.
|March 8, 2007||Testing Embryos for Diseases (ABC News)
How far would you go to prevent passing a deadly disease on to your children?
IHR offers a variety of Financial Options and Insurance Carriers
While you are in IHR care, we want to provide you with the highest quality of care available in a compassionate and cost effective manner. Our fertility treatment programs are structured to encourage a high level of personal contact with your medical and financial team and we encourage you to utilize these resources.
The extent of coverage, benefits, referral and authorization process vary from policy to policy. It is important that you understand what is covered before you begin treatment, or what the necessary requirements are in order to get the maximum reimbursement. The finance department can provide some general guidelines on most common policies within each plan, but ultimately it is your responsibility to understand your infertility treatment coverage under your plan.
Our billing/insurance team will be able to answer any questions regarding fee schedules, insurance issues, payment options, etc. Please feel free to contact us at 773.472.4949.
The Institute for Human Reproduction receives correspondence from around the world. We will consider adding your link to our website in exchange for being listed on yours. To arrange, please contact us.
The following websites have listed us on their website:
- Cyto Resource
- Gene Tests
- National Technological University
- PGD International Society
- Reproductive Bio-Medicine Online
- World Health Organization
- Genetic Screening
- Public Health Genetics
- IVF Institute
- BBC News
- Umbilical Cord Blood
- UK Genetic Testing
- Stem Cell
- UK Listing
- Hasten down the wire
- BBC News
- Gary Spatz Acting School
- Reason Online
- Cystic Fibrosis
- Studio Recording